Daniel C. Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel C. Chung has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Andrew T. Chan
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
23 shared publications - David Alden Drew
Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
23 shared publications - Alexander Caraballo
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 7
22 shared publications - Alice E. Shin
Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, USA
22 shared publications - Carmen Rios
Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Boston, Massachusetts. 10
22 shared publications - Chi-Lee C. Ho
Department of Surgery, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. 1
22 shared publications
Latest Publications
- 9 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- p. OF1-OF6
Long-term Endoscopic Surveillance in Hereditary Diffuse Gastric Cancer Syndrome
Hereditary diffuse gastric cancer (HDGC) syndrome arises from a germline variant in CDH1 and is characterized by a high risk of gastric signet-ring cell carcinoma (SRCC). Total gastrectomy is the most definitive strategy for cancer risk reduction but carries high morbidity. Endoscopic surveillance is an alternative, but there are limited data on long-term outcomes with this approach. We sought to define the outcomes of long-term endoscopic surveillance in a HDGC cohort. We retrospectively analyzed the demographic, clinical, endoscopic, and histopathologic records of 102 patients with pathogenic or likely pathogenic (P/LP) CDH1 variants at Massachusetts General Hospital (MGH). We defined short-term endoscopic surveillance as less than 3 years and long-term surveillance as 3 years or longer. The HDGC cohort included 68 female and 34 male patients, with a mean age at diagnosis of 42.1 years. Thirty-four patients opted for immediate risk-reducing gastrectomy, and 40 pursued endoscopic surveillance. Twenty individuals comprised the short-term surveillance group (median follow-up, 1.4 years), and 20 individuals comprised the long-term surveillance group (median follow-up, 5.1 years). There were two cases of advanced gastric cancer (>T1a) identified, and both occurred in the long-term surveillance group. Both were managed with gastrectomy and remain cancer free. There were no gastric cancer-related deaths. In this series, long-term endoscopic surveillance identified advanced gastric cancers in HDGC at treatable stages without any gastric cancer–related mortality. These findings suggest that endoscopic surveillance may be a reasonable long-term strategy in HDGC for select individuals. Prevention Relevance: The optimal strategy for early detection of gastric cancer in the HDGC syndrome is uncertain. Our data provide new long-term evidence that endoscopic surveillance may be an appropriate strategy that avoids the profound morbidities of prophylactic total gastrectomy.
- 9 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- p. OF1-OF6
Long-term Endoscopic Surveillance in Hereditary Diffuse Gastric Cancer Syndrome
Hereditary diffuse gastric cancer (HDGC) syndrome arises from a germline variant in CDH1 and is characterized by a high risk of gastric signet-ring cell carcinoma (SRCC). Total gastrectomy is the most definitive strategy for cancer risk reduction but carries high morbidity. Endoscopic surveillance is an alternative, but there are limited data on long-term outcomes with this approach. We sought to define the outcomes of long-term endoscopic surveillance in a HDGC cohort. We retrospectively analyzed the demographic, clinical, endoscopic, and histopathologic records of 102 patients with pathogenic or likely pathogenic (P/LP) CDH1 variants at Massachusetts General Hospital (MGH). We defined short-term endoscopic surveillance as less than 3 years and long-term surveillance as 3 years or longer. The HDGC cohort included 68 female and 34 male patients, with a mean age at diagnosis of 42.1 years. Thirty-four patients opted for immediate risk-reducing gastrectomy, and 40 pursued endoscopic surveillance. Twenty individuals comprised the short-term surveillance group (median follow-up, 1.4 years), and 20 individuals comprised the long-term surveillance group (median follow-up, 5.1 years). There were two cases of advanced gastric cancer (>T1a) identified, and both occurred in the long-term surveillance group. Both were managed with gastrectomy and remain cancer free. There were no gastric cancer-related deaths. In this series, long-term endoscopic surveillance identified advanced gastric cancers in HDGC at treatable stages without any gastric cancer–related mortality. These findings suggest that endoscopic surveillance may be a reasonable long-term strategy in HDGC for select individuals. Prevention Relevance: The optimal strategy for early detection of gastric cancer in the HDGC syndrome is uncertain. Our data provide new long-term evidence that endoscopic surveillance may be an appropriate strategy that avoids the profound morbidities of prophylactic total gastrectomy.
- 1 September 2026
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 55  (4)
Genetic Disorders and Genetic Testing in Gastroenterology
- 1 September 2026
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 55  (4)
Genetic Disorders and Genetic Testing in Gastroenterology
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- Open Access
- 19 March 2026
- Published by Oxford University Press (OUP) in Research Connections
- Vol. 1  (2)
Feasibility and Acceptability of an Electronic Decision Aid for Genetic Testing in Ovarian and Pancreatic Cancer Patients
Background and Aims: Germline genetic testing is recommended for all patients with ovarian or pancreatic cancer, and alternative service delivery models are needed to meet this demand. We evaluated an electronic decision aid (DA) that can be administered during a visit with an oncology provider. The DA centered around the decision to pursue genetic testing and selection of a specific multi-gene panel. Methods: An electronic DA had previously been developed by a multi-disciplinary team. Patients were enrolled at two academic medical centers. We surveyed participants with ovarian or pancreatic cancer who completed the DA about their experience and knowledge gained. Oncology providers were also surveyed. Results: 92 patients were enrolled. The DA took 13.7 minutes to complete. There was a 20% increase in knowledge scores after using the DA. 95% opted to pursue genetic testing; 20% chose the smallest cancer-specific gene panel, 31% chose the mid-size multi-cancer panel, and 49% chose the largest panel that included limited evidence genes. Nearly all participants (93%) indicated the DA helped their decision-making and 95% would recommend the DA to friends interested in genetic testing. 91% of providers felt patients were well-informed about genetic testing options and 93% indicated the DA did not extend appointment times. Conclusions: Use of a DA for genetic testing is feasible and acceptable. Patients and providers expressed high levels of satisfaction. The wide range of multi-gene panels selected highlights the importance of offering choice. Studies to formally compare the performance of the DA with traditional genetic counseling are warranted.
- 19 March 2026
- Published by Oxford University Press (OUP) in Research Connections
- Vol. 1  (2)
Open AccessFeasibility and Acceptability of an Electronic Decision Aid for Genetic Testing in Ovarian and Pancreatic Cancer Patients
Background and Aims: Germline genetic testing is recommended for all patients with ovarian or pancreatic cancer, and alternative service delivery models are needed to meet this demand. We evaluated an electronic decision aid (DA) that can be administered during a visit with an oncology provider. The DA centered around the decision to pursue genetic testing and selection of a specific multi-gene panel. Methods: An electronic DA had previously been developed by a multi-disciplinary team. Patients were enrolled at two academic medical centers. We surveyed participants with ovarian or pancreatic cancer who completed the DA about their experience and knowledge gained. Oncology providers were also surveyed. Results: 92 patients were enrolled. The DA took 13.7 minutes to complete. There was a 20% increase in knowledge scores after using the DA. 95% opted to pursue genetic testing; 20% chose the smallest cancer-specific gene panel, 31% chose the mid-size multi-cancer panel, and 49% chose the largest panel that included limited evidence genes. Nearly all participants (93%) indicated the DA helped their decision-making and 95% would recommend the DA to friends interested in genetic testing. 91% of providers felt patients were well-informed about genetic testing options and 93% indicated the DA did not extend appointment times. Conclusions: Use of a DA for genetic testing is feasible and acceptable. Patients and providers expressed high levels of satisfaction. The wide range of multi-gene panels selected highlights the importance of offering choice. Studies to formally compare the performance of the DA with traditional genetic counseling are warranted.